Huprine Derivatives as Sub‐Nanomolar Human Acetylcholinesterase Inhibitors: From Rational Design to Validation by X‐ray Crystallography

No abstract is available for this paper.

• Publication year

  2012

• Venue

  ChemMedChem

• Publication date

  2012-03-05

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/cmdc.201100438PMID 22052791
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's disease

  2013cited by this paper
• New potent human acetylcholinesterase inhibitors in the tetracyclic triterpene series with inhibitory potency on amyloid β aggregation.

  2011cited by this paper
• New Huprine Derivatives Functionalized at Position 9 as Highly Potent Acetylcholinesterase Inhibitors

  2011cited by this paper
• Secretases as therapeutic targets for Alzheimer's disease.

  2011cited by this paper
• Benzophenone-based derivatives: a novel series of potent and selective dual inhibitors of acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.

  2011cited by this paper
• Design, synthesis and evaluation of novel tacrine-multialkoxybenzene hybrids as dual inhibitors for cholinesterases and amyloid beta aggregation.

  2011cited by this paper
• Crystal structures of oxime-bound fenamiphos-acetylcholinesterases: reactivation involving flipping of the His447 ring to form a reactive Glu334-His447-oxime triad.

  2010cited by this paper
• Improved synthetic pathway for the derivatization of huprine scaffold

  2010cited by this paper
• gamma-Secretase as a therapeutic target in Alzheimer's disease.

  2010cited by this paper
• The secretases: enzymes with therapeutic potential in Alzheimer disease

  2010cited by this paper
• ?-Secretase as a Therapeutic Target in Alzheimer's Disease

  2010cited by this paper
• Novel Huprine Derivatives with Inhibitory Activity toward β‐Amyloid Aggregation and Formation as Disease‐Modifying Anti‐Alzheimer Drug Candidates

  2010cited by this paper
• Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.

  2009cited by this paper
• Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks.

  2009cited by this paper
• Structural characterization of a soluble amyloid beta-peptide oligomer.

  2009cited by this paper
• Structure–neurotoxicity relationships of amyloid β-protein oligomers

  2009cited by this paper
• Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease

  2008cited by this paper
• Amyloid–cholinesterase interactions

  2008cited by this paper
• Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush.

  2008cited by this paper
• Flexibility of aromatic residues in the active-site gorge of acetylcholinesterase: X-ray versus molecular dynamics.

  2008cited by this paper
• Multi-target-directed ligands to combat neurodegenerative diseases.

  2008cited by this paper
• Click chemistry reactions in medicinal chemistry: Applications of the 1,3‐dipolar cycloaddition between azides and alkynes

  2008cited by this paper
• Click Chemistry and Medicinal Chemistry: A Case of “Cyclo‐Addiction”

  2008cited by this paper
• Changing the course of Alzheimer's disease: anti-amyloid disease-modifying treatments on the horizon.

  2007cited by this paper
• Alzheimer disease: progress or profit?

  2006cited by this paper
• Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors.

  2006cited by this paper
• Multifunctional neuroprotective drugs for the treatment of cognitive and movement impairment disorders, including Alzheimer's and Parkinson's diseases

  2006cited by this paper
• Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease.

  2005cited by this paper
• Synthesis and pharmacological evaluation of huprine-tacrine heterodimers: subnanomolar dual binding site acetylcholinesterase inhibitors.

  2005cited by this paper
• Deciphering the molecular basis of memory failure in Alzheimer's disease.

  2004cited by this paper
• Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors.

  2003cited by this paper
• 3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 A resolution: kinetic and molecular dynamic correlates.

  2002cited by this paper
• New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease.

  2000cited by this paper
• Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease.

  1999cited by this paper
• The cholinergic hypothesis of Alzheimer’s disease: a review of progress

  1999cited by this paper
• Highly Potent, Selective, and Low Cost Bis-tetrahydroaminacrine Inhibitors of Acetylcholinesterase

  1996cited by this paper
• Mechanisms of neuronal degeneration in Alzheimer's disease.

  1996cited by this paper
• Acetylcholinesterase inhibition by fasciculin: crystal structure of the complex.

  1995cited by this paper
• Acetylcholinesterase, a senile plaque component, affects the fibrillogenesis of amyloid-beta-peptides.

  1995cited by this paper
• Acetylcholinesterase, a senile plaque component, affects the fibrillogenesis of amyloid-β-peptides

  1995cited by this paper
• Crystal structure of an acetylcholinesterase-fasciculin complex: interaction of a three-fingered toxin from snake venom with its target.

  1995cited by this paper
• Alzheimer's Disease: A Central Role for Amyloid

  1994cited by this paper
• The amyloid deposits in Alzheimer's disease: their nature and pathogenesis.

  1984cited by this paper
• Alzheimer's disease: a disorder of cortical cholinergic innervation.

  1983cited by this paper
• Synthetic applications and mechanism studies of the decarbalkoxylations of geminal diesters and related systems effected in dimethyl sulfoxide by water and/or by water with added salts

  1978cited by this paper
• Biological Crystallography Structures of Recombinant Native and E202q Mutant Human Acetylcholinesterase Complexed with the Snake-venom Toxin Fasciculin-ii

  year unknowncited by this paper

• Biofunctional MIL-53(Fe) frameworks functionalized with 3-amino-1,2,4-triazole and gallic acid: experimental and computational insights into DNA binding and drug delivery

  2026cites this paper
• Exploring Pyridinium-Based Inhibitors of Cholinesterases: A Review of Synthesis, Efficacy, and Structural Insights

  2025cites this paper
• Applications of Bridgehead Heterocycles in Drug Design and Medicinal Chemistry

  2025cites this paper
• A recent update on huprine and its hybrids as a potential multifunctional agent for the treatment of Alzheimer's disease

  2024cites this paper
• Light-Induced Unlocking Reactivity of Fragments for Fast Target-Guided Synthesis of Carbonic Anhydrase Inhibitors.

  2024cites this paper
• Acetylcholinesterase-responsive fluorescent probe: Recent advances from development to applications

  2023cites this paper
• Huprine Y - tryptophan heterodimers with potential implication to Alzheimer's disease treatment.

  2021cites this paper
• In silico Analysis of Alkaloids for Therapeutic Use in Treatment of Alzheimer's Disease by Targeting Acetylcholinesterase Enzyme

  2021cites this paper
• Efficacy Assessment of an Uncharged Reactivator of NOP-Inhibited Acetylcholinesterase Based on Tetrahydroacridine Pyridine-Aldoxime Hybrid in Mouse Compared to Pralidoxime

  2020cites this paper
• The Friedländer reaction: A powerful strategy for the synthesis of heterocycles

  2020cites this paper
• Discovery of a Potent Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase with Antioxidant Activity that Alleviates Alzheimer-like Pathology in Old APP/PS1 Mice.

  2020cites this paper
• Synthesis and biological evaluation of 3-amino-1,2,4-triazole derivatives as potential anticancer compounds.

  2020cites this paper
• The Structural Hybrids of Acetylcholinesterase Inhibitors in the Treatment of Alzheimer’s Disease: A Review

  2019cites this paper
• New amyloid beta-disaggregating agents: synthesis, pharmacological evaluation, crystal structure and molecular docking of N-(4-((7-chloroquinolin-4-yl)oxy)-3-ethoxybenzyl)amines.

  2018cites this paper
• Increasing Polarity in Tacrine and Huprine Derivatives: Potent Anticholinesterase Agents for the Treatment of Myasthenia Gravis

  2018cites this paper
• The Targeted Pesticides as Acetylcholinesterase Inhibitors: Comprehensive Cross-Organism Molecular Modelling Studies Performed to Anticipate the Pharmacology of Harmfulness to Humans In Vitro

  2018cites this paper
• Recent developments in structural studies on acetylcholinesterase

  2017cites this paper
• 5-Methyl-N-(8-(5,6,7,8-tetrahydroacridin-9-ylamino)octyl)-5H-indolo[2,3-b]quinolin-11-amine: a highly potent human cholinesterase inhibitor.

  2017cites this paper
• Comparison of the Binding of Reversible Inhibitors to Human Butyrylcholinesterase and Acetylcholinesterase: A Crystallographic, Kinetic and Calorimetric Study

  2017cites this paper
• Design, synthesis and biological evaluation of N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors.

  2016influential citation
• Applications of Click Chemistry in Drug Discovery and Development

  2016cites this paper
• Slow-binding inhibition of acetylcholinesterase by an alkylammonium derivative of 6-methyluracil: mechanism and possible advantages for myasthenia gravis treatment.

  2016cites this paper
• Improved Access to Huprine Derivatives Functionalized at Position 9

  2016cites this paper
• A selective and sensitive near-infrared fluorescent probe for acetylcholinesterase imaging.

  2016cites this paper
• Exploring heterocyclic scaffolds in the development of multi-target anti-Alzheimer and multi-trypanosomatid compounds

  2015cites this paper
• New insights into the kinetic target-guided synthesis of protein ligands.

  2015cites this paper
• Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes. Update 2014

  2014cites this paper
• Multitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid-β aggregation and to exert anticholinesterase and antioxidant effects.

  2014cites this paper
• Reaction site-driven regioselective synthesis of AChE inhibitors.

  2014cites this paper
• Correlation of the dynamics of native human acetylcholinesterase and its inhibited huperzine A counterpart from sub-picoseconds to nanoseconds

  2014cites this paper
• Crystal structures of human cholinesterases in complex with huprine W and tacrine: elements of specificity for anti-Alzheimer's drugs targeting acetyl- and butyryl-cholinesterase.

  2013cites this paper
• A step toward the reactivation of aged cholinesterases--crystal structure of ligands binding to aged human butyrylcholinesterase.

  2013cites this paper
• Radiosynthesis and in vivo evaluation of fluorinated huprine derivates as PET radiotracers of acetylcholinesterase.

  2013cites this paper
• Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes

  2013cites this paper
• Bivalent Organophosphorus Compounds—Synthesis and Acetylcholinesterase Inhibitory Activity

  2013cites this paper
• Energy landscapes of human acetylcholinesterase and its Huperzine A-inhibited counterpart.

  2012cites this paper
• Human butyrylcholinesterase produced in insect cells: huprine‐based affinity purification and crystal structure

  2012cites this paper
• Screening of new huprines--inhibitors of acetylcholinesterases by electrospray ionization ion trap mass spectrometry.

  2012cites this paper